Recently, Sansure and Singlera jointly established Jiangsu Yang Shengyuan Biotechnology Co., Ltd. with the registered capital of 10 million CNY at Yangzhou City.

On February 20, Roche Group and Zhuhai People's Hospital Medical Group formally signed a strategic cooperation agreement.

Genomic and diagnostic testing company Prenetics Global said Tuesday that the US Food and Drug Administration has cleared ACTOnco, a comprehensive genomic profiling test for solid tumors.

Foundation Medicine and Karyopharm Therapeutics said Tuesday they are collaborating on a companion diagnostic for Karyopharm's experimental drug Xpovio (selinexor), which is in development as a maintenance therapy for patients with advanced or recurrent TP53 wild-type endometrial cancer.

Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Natera, Inc., a global leader in cell-free DNA testing, today launched an early access program for clinical use of FoundationOne®Tracker, a personalized circulating tumor DNA (ctDNA) monitoring assay.

TÜV SÜD said recently that it has certified a companion diagnostic manufactured by Roche under the EU's new In Vitro Diagnostic Regulation, adding it is the first such certification for a CDx.

Foundation Medicine said Wednesday its FoundationOne Liquid CDx test has received approval from the US Food and Drug Administration as a companion diagnostic for Genentech's Rozlytrek (entrectinib).

Foundation Medicine said Wednesday its FoundationOne Liquid CDx test has been approved by the US Food and Drug Administration as a companion diagnostic for epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI).

A team from Stanford University, Columbia University, the New York Genome Center, and elsewhere has uncovered somatic tandem repeat expansions in tumors from a wide range of cancer types, including a potentially targetable repeat expansion in a subset of kidney cancers.

A new UC San Francisco study sheds light on the diversity within the most common type of pediatric liver tumor and suggests a way forward for more precise chemotherapy treatment.